Op vrijdag heeft BMO Capital Markets het koersdoel voor de aandelen van Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) verhoogd van $520 naar $545, terwijl het Outperform-advies werd gehandhaafd.
A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...
VRTX insiders have traded $VRTX stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales. Here’s a ...
Get Wall Street's Hottest Chart Every Morning RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback